A common diabetes drug is linked to less breast cancer spread
Original title: SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This came from looking back at patient records, not from a trial that tested the drug for this use.
The short version
Women who took a certain diabetes drug were less likely to have their breast cancer spread to other organs.
What was studied. Researchers looked back at health records from a large global network. They compared 3569 women who started SGLT2 inhibitor diabetes drugs after breast cancer surgery with 3569 similar women who took other diabetes drugs.
What they found. The women on SGLT2 inhibitors had a lower risk of their cancer spreading to distant parts of the body. The difference was biggest for spread to the liver, then the lungs and the bones. There was no clear difference for spread to the brain.
What this means, and what it doesn't
What it could mean: If you have breast cancer and type 2 diabetes, which diabetes drug you take may matter. That is a fair question to bring up with your own doctor. It is not a reason to start or switch any medicine on your own.
What it doesn't mean: This does not mean the drug stops cancer from spreading. The study only looked back at records that already existed. It did not test the drug in a planned trial. A study like this can show a link, but it cannot show that the drug caused the difference. The authors say planned trials are needed before care should change. This is not a cancer treatment and it is not a cure.
Source: PubMed, July 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.